News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Alkermes
NEWS
JOBS
IN THE PRESS
NEWS
Drug Development
Alkermes Rockets as Depression Drug Aces Key Late-Stage Trial
October 21, 2016
·
2 min read
Pharm Country
How Alkermes Transformed an Anti-Addiction Drug From a Bust to a Hit
September 28, 2016
·
2 min read
Drug Development
Stock Craters as Alkermes’ Depression Drug Fails in Two Late-Stage Trials
January 21, 2016
·
3 min read
Job Trends
1,075 New Jobs to be Added by 11 Life Science Firms in Massachusetts: Amgen, Alnylam, Biogen Idec, Inc. (North Carolina), GE Healthcare Bio-Sciences, Quest Diagnostics, Alkermes, Baxter Healthcare, Merrimack, Synageva BioPharma, Philips Electronics, SMC
March 19, 2015
·
2 min read
Deals
Alkermes Dumps Georgia Facility, Pain Drug Rights to Recro Pharma in $170 Million+ Deal
March 9, 2015
·
2 min read
BioCapital
2015 Could Be Blockbuster Year for Alkermes plc, Says Citi
December 17, 2014
·
2 min read
Genetown
Alkermes plc CEO’s Take On Building Big, Playing Well With Pharma
April 21, 2014
·
1 min read
Pharm Country
How One Biotech Company, Alkermes plc, Survived A Brush With Death
November 11, 2013
·
1 min read
BioCapital
Exenatide Clinical Data Analysis Shows No Increased Risk Of Cardiovascular Events, Amylin Pharmaceuticals, Inc., Eli Lilly and Company And Alkermes Announce
March 27, 2009
·
1 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
January 6, 2026
·
5 min read
Press Releases
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 30, 2025
·
1 min read
Press Releases
Alkermes to Participate in Two Upcoming December 2025 Investor Conferences
November 26, 2025
·
1 min read
Press Releases
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
November 13, 2025
·
11 min read
Press Releases
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
July 21, 2025
·
11 min read
Press Releases
Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024
September 23, 2024
·
9 min read
Drug Development
Journal of Clinical Psychiatry Publishes Data from Alkermes’ ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness
March 23, 2023
·
15 min read
Alkermes to Participate in the Stifel 2023 CNS Days
March 15, 2023
·
1 min read
Business
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023
February 16, 2023
·
23 min read
Business
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023
February 9, 2023
·
1 min read
